Brief: Oryzon Announces Positive Clinical Data Of Iadademstat At ASH-2025

ORYZON Genomics SA

04/11/2025 07:21

Nov 4 (Reuters) - Oryzon Genomics SA ORY.MC:

ANNOUNCES POSITIVE CLINICAL DATA OF IADADEMSTAT AT ASH-2025

PRELIMINARY DATA FROM ONGOING PHASE IB TRIAL COMBINING IADADEMSTAT WITH AZACITIDINE AND VENETOCLAX IN NEWLY DIAGNOSED, UNFIT AML PATIENTS SHOWED 100% OVERALL RESPONSE RATE

UPDATED PRELIMINARY DATA FROM ONGOING PHASE IB FRIDA TRIAL EVALUATING IADADEMSTAT JOINT WITH GILTERITINIB IN FLT3-MUTATED RELAPSED/REFRACTORY AML SHOWED 67% RESPONSE RATE IN EXPANDED DOSE

Source text: ID:nCNMHBDBy

Further company coverage: ORY.MC

 (Gdansk Newsroom)

 ((Gdansk.newsroom@thomsonreuters.com;))